Search Within

Shanu Modi

Formats
  1. Meeting Abstract (151)
  2. Journal Article (101)
  3. Review (12)
  4. Correspondence (2)
  5. Editorial (2)
  6. Research Letter (1)
Groups
  1. Breast Medicine Service (269)
  2. Department of Medicine (269)
  3. Solid Tumor Oncology Division (269)
  4. Survivorship Research (114)
  5. GSK Faculty (108)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (91)

More Groups

People
  1. Clifford Hudis (79)
  2. Larry Norton (53)
  3. Sarat Chandarlapaty (51)
  4. Sujata Patil (44)
  5. Chau Dang (42)
  6. Komal Jhaveri (35)

More People

Years
  1. 2025 (9)
  2. 2024 (23)
  3. 2023 (15)
  4. 2022 (19)
  5. 2021 (19)
  6. 2020 (21)

More Years

Publications
  1. Journal of Clinical Oncology (66)
  2. Cancer Research (50)
  3. Annals of Oncology (27)
  4. Breast Cancer Research and Treatment (14)
  5. Clinical Cancer Research (10)
  6. Clinical Breast Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (68)
  2. American Association for Cancer Research (64)
  3. Oxford University Press (33)
  4. Elsevier Inc. (19)
  5. Springer (19)
  6. Nature Publishing Group (13)

More Publishers

Results (269)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The genomic landscape of breast cancer in African American women
    Meeting Abstract

    Serna-Tamayo, C.; Drago, J. Z.; Dos Anjos, C.; Herbert, J.; Pareja, F.; Modi, S.; Jhaveri, K.; Dang, C.; Solit, D. B.; Norton, L.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • A phase 3, multicenter, randomized, open-label trial of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)
    Meeting Abstract

    Modi, S.; Ohtani, S.; Lee, C.; Wang, Y.; Saxena, K.; Cameron, D. A.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)
    Meeting Abstract

    Krop, I. E.; Saura, C.; Yamashita, T.; Park, Y. H.; Kim, S. B.; Tamura, K.; AndreĢ, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Genomic profiling of primary and metastatic breast cancer in men
    Meeting Abstract

    Drago, J. Z.; Serna-Tamayo, C.; Dos Anjos, C. H.; Brown, D. N.; Modi, S.; Jhaveri, K.; Solit, D. B.; Traina, T. A.; Chandarlapaty, S.; Reis-Filho, J. S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase Ib study
    Journal Article

    Modi, S.; Park, H.; Murthy, R. K.; Iwata, H.; Tamura, K.; Tsurutani, J.; Moreno-Aspitia, A.; Doi, T.; Sagara, Y.; Redfern, C.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
    Journal Article

    Modi, S.; Saura, C.; Yamashita, T.; Park, Y. H.; Kim, S. B.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; more...
    New England Journal of Medicine (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of gemcitabine with trastuzumab and pertuzumab after prior pertuzumab-based therapy among patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A phase 2 clinical trial
    Journal Article

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Fornier, M. N.; Goldfarb, S.; Jhaveri, K.; more...
    JAMA Network Open (2019)

    Fulltext@MSK | Save
  • Paradigms for precision medicine in epichaperome cancer therapy
    Journal Article

    Pillarsetty, N.; Jhaveri, K.; Taldone, T.; Caldas-Lopes, E.; Punzalan, B.; Joshi, S.; Bolaender, A.; Uddin, M. M.; Rodina, A.; Yan, P.; more...
    Cancer Cell (2019)

    Fulltext@MSK | Save
  • Adjuvant enzalutamide for the treatment of early-stage androgen receptor-positive (AR plus ) TNBC
    Meeting Abstract

    Traina, T. A.; Boyle, L. A.; Arumov, A.; Patil, S.; Edelweiss, M.; DeFusco, P. A.; Gorsky, M.; Lamparella, N. E.; Modi, S.; Sanford, R. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase III, multicenter, randomized, open label trial of [fam-] trastuzumab deruxtecan (DS-8201a) versus investigator's choice in HER2-low breast cancer
    Meeting Abstract

    Modi, S.; Ohtani, S.; Lee, C. C.; Wang, K.; Saxena, K.; Cameron, D. A.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save